AP NEWS
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from ACCESSWIRE
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.

Edison issues ADR update on Hutchison China MediTech (HCM)

November 29, 2019
LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration ...
LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration ...

LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Although expected, this is a huge positive as from 1 January 2020 Elunate will be available in all state-run hospital pharmacies and patients on NHSA insurance schemes will be reimbursed. HCM’s innovative oncology assets are making significant progress in China. It has now submitted the China NDA for surufatinib for treating non-pancreatic NET tumors, a large unmet clinical need. Surufatinib is likely to be the first of HCM’s non-partnered assets to reach the China market (late 2020). We value HCM at $5.7bn.

Our valuation of HCM is unchanged at $5.7bn and make no changes to our forecasts. We use a risk-adjusted net present value method to discount future cash flows for the innovation platform (savolitinib, fruquintinib, surufatinib, epitinib, HMPL-523 and HMPL-689) valuation of $4,131.4m.

Click here to view the full report.

Subscribe to Edison’s content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Dr Susie Jana, +44 (0)20 3077 5700

Dr Daniel Wilkinson, +44 (0)20 3077 5734

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited

View source version on accesswire.com: